Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study

Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high‐risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4–7, enrolled in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchings, Martin, Radford, John, Ansell, Stephen M., Illés, Árpád, Sureda, Anna, Connors, Joseph M., Sýkorová, Alice, Shibayama, Hirohiko, Abramson, Jeremy S., Chua, Neil S., Friedberg, Jonathan W., Kořen, Jan, LaCasce, Ann Steward, Molina, Lysiane, Engley, Gerald, Fenton, Keenan, Jolin, Hina, Liu, Rachael, Gautam, Ashish, Gallamini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247884/
https://www.ncbi.nlm.nih.gov/pubmed/33462822
http://dx.doi.org/10.1002/hon.2838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247884/
https://www.ncbi.nlm.nih.gov/pubmed/33462822
http://dx.doi.org/10.1002/hon.2838

Ejemplares similares